NORTH CHICAGO, Ill., April 7, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2014 financial results on Friday, April 25, 2014, before the market opens.
NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12.
NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis.
BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12 weeks of treatment with AbbVie's investigational therapy with or without ribavirin (RBV) in non-cirrhotic, adult patients with chronic genotype 1b (GT1b) hepatitis C virus (HCV) infection who were new to treatment.
NORTH CHICAGO, Ill., Feb. 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference 2014 on Thursday, March 13, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:30 a.m. Central time.
NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 5 percent from $0.40 per share to $0.42 per share.
NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- AbbVie today announced the launch of 'Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases (IMIDs) and their impact on patients and society. More than 100 unique artistic expressions from the initiative are being debuted at the 9th Congress of the European Crohn's and Colitis Organisation (ECCO) in Copenhagen, Denmark from February 20th to 22nd.
NORTH CHICAGO, Ill., Feb. 19, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:40 a.m. Central time.
NORTH CHICAGO, Ill., Feb. 5, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) announces a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally.
NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. These results described below confirm previously reported AbbVie data and further demonstrate high sustained virologic response rates 12 weeks post treatment (SVR12) and tolerability in these GT1 patients.
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.
Stay up to date on recent news, articles, and more by subscribing to email alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?